Clinical Trial Update: The Effectiveness of Nivolumab Monotherapy as First-Line Therapy in Adults With Advanced Melanoma in Germany

View source ↗

Summary

A clinical trial evaluating nivolumab monotherapy as first-line treatment for adults with advanced melanoma in Germany has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• nivolumab (nivolumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Melanoma | Status: WITHDRAWN